ATAI - Atai Life Sciences N.V.
After hours:
| Previous Close | 1.7700 |
| Open | 1.7900 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 2900 |
| Day's Range | 1.7200 - 1.8200 |
| 52 Week Range | 1.1400 - 4.9600 |
| Volume | |
| Avg. Volume | 1,154,303 |
| Market Cap | 293.838M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8900 |
| Earnings Date | May 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.15 |
GlobeNewswireatai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia.GRX-917: Presented PD data from the completed Phase 1 study, which suggest the potential for anxiolytic effects without the significant sedative effects seen with benzodiazepines.VLS-01: Well-tolerated in Parts 1 (IV) and 2 (OTF) of the on-going Phase 1 study. Amended protocol to expand study into Part 3, which is expected to further optimize the PK and PD of our proprietary OTF form
- GlobeNewswire
atai Life Sciences to Participate in Upcoming May Investor Conference
NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Aegis Virtual Conference. Details of the company’s presentation is as follows: Aegis Virtual ConferenceFormat: Corporate PresentationDate and Time: Wednesday, May 3rd, 11:30 a.m. ETLocation: Virtual A live webcast of the presentation will be available on atai’s websit
- GlobeNewswire
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
- Pharmacodynamic profile of GRX-917 indicates potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that pharmacodynamic data on GRX-917, a deuterated version of etifoxine, was selected for poster presentation and presented ye
- GlobeNewswire
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). This Phase 1 open-label study is designed to assess the safety, tolerability, and pharmacokinetic profile of 60mg, 90mg and 120mg of PCN-101 d
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Aurora announced the repurchase of convertible senior notes worth approximately $47 million, saving the company $2.6 million in annualized interest payments. Jushi Holdings reported preliminary Q4 and record full year 2022 financial results. Curaleaf announced $20 million acquisition in Key Takeaways; Psychedelic Sector Awakn’s proprietary treatment protocol for alcohol use disorder […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared fi
- GlobeNewswire
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditionsContinued operational progress on robust clinical pipeline, with multiple phase 1 and phase 2 proof-of-concept datasets expected in the next two years$273 million in cash, cash equivalents and short-term investments at end of 2022 and access to a term loan facility of up to an additional $160 million provide anticipated
- GlobeNewswire
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
RL-007: First patient dosed in the on-going phase 2b study in cognitive impairment associated with schizophreniaGRX-917: Intention to progress GRX-917 into a phase 2 study in an anxiety disorder as the next step in clinical developmentCOMP360: Recently announced acceleration of the Pivotal Trial 1 (COMP 005) part of the phase 3 program, with top line data now expected in the summer of 2024Corporate: As a result of our recent restructuring and pipeline updates, the company has extended its cash r
- GlobeNewswire
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference. Details of the company’s panel participation are as follows: Cowen 43rd Annual Health Care Conference Format: Neuropsych Corporate Panel Date and Time: Monday, March 6th, 12:50 p.m. – 1:20 p.m. ET Location: Boston, MA A live webc
- News Direct
Trippy Trading: Top Psychedelic Stocks For 2023
When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus, scie...
- GlobeNewswire
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
GRX-917 (deuterated etifoxine) was well-tolerated with no dose-limiting toxicities and only mild adverse effects comparable to that of placebo in both single and multiple ascending doses, as previously announced as preliminary results during atai’s R&D day.Final results demonstrate target engagement of GRX-917 via dose-related activation of quantitative electroencephalography (qEEG) frontal beta power, a biomarker for GABA-A receptor-associated anxiolytic activity, consistent with GRX-917’s puta
- GlobeNewswire
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, Perception Neuroscience’s Phase 2a clinical trial did not meet its primary endpoint of a statistically significant change from baseline in participants’ MADRS (Montgomery-Åsberg Depression Rating Sc
- GlobeNewswire
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
- This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of KUR-101 - KUR-101 was well tolerated and demonstrated analgesic activity in two experimental pain models - An assessment of the respiratory impact of KUR-101 was inconclusive as the positive control, oxycodone, failed to separate from placebo - KUR-101, a deuterated derivative of mitragynine, is a low-potency, partial mu-opioid receptor (MOR) agonist designed to prod
- GlobeNewswire
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS).The trial was initiated and has begun patient screening this month with first-patient-in anticipated by end-of-year.There are currently no FDA-approved medications for CIAS, a major cause of disability in 80% of patients with schizophrenia1.Topline results are expected in the first half of 2024. NEW YORK and BERLIN, Dec
- GlobeNewswire
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massachusetts General Hospital (“MGH”) Center for the Neuroscience of Psychedelics. The $2 million Fellowship Fund was announced in December 2021 to facilitate research into the potential of psychedelics to address unmet patient needs in ment
- GlobeNewswire
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee - - He has spent more than 15 years building and growing organizations and businesses in the life sciences and digital health industries - - His deal sheet includes transactions totaling more than USD 2.7 billion in CNS and beyond - NEW YORK and BERLIN, Nov. 29, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V., (NASDAQ: ATAI) (“atai” or the “Company”
- GlobeNewswire
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study with Massachusetts General Hospital (MGH). The study will utilize a neuroimaging method to identify neuroplasticity biomarkers in patients with treatment-resistant depression (TRD) undergoing intravenous (IV) ketamine treatment. The main obj
- GlobeNewswire
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
Last patient dosed in the Phase 2a proof-of-concept trial of PCN-101 (R-ketamine) for treatment-resistant depression (TRD), with topline results expected around year-end 2022.Announced positive preliminary pharmacokinetics and pharmacodynamics results in a Phase 1 study of GRX-917 (deuterated etifoxine) being developed for generalized anxiety disorder (GAD), demonstrating target engagement based on qEEG. Announced positive preliminary results of the single ascending dose (SAD) portion of the Pha
Business WireWomen in Psychedelics Announces atai as Platinum Sponsors
TORONTO, November 04, 2022--The Women in Psychedelics Network ("WIPN" or "Network"), a network of professionals from all corners of the psychedelic industry strengthening women’s voices and providing opportunities to move mental health solutions forward, today announced atai Life Sciences N.V. (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, as a platinum sponsor of the Network, through its philanthropic arm atai Im
- GlobeNewswire
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences: Financial Times Pharma and Biotech Summit in LondonFormat: Industry PanelDate and Time: Wednesday, November 9th, 9:55 a.m. – 10:40 a.m. ETConference link: Financial Times’ Pharma and Biotech Summit Credit Suisse Ann
- GlobeNewswire
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its third quarter 2022 financial results and business update on Thursday, November 10, 2022. A video interview with atai management will be available at 8:30 a.m. (ET) at https://vimeo.com/atailifesciences. The archived video will be available in the “Events” section of th
- GlobeNewswire
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine).Last patient expected to be dosed this week, with the total number of patients expected to be around 100. Topline results expected around year-end 2022.PCN-101 is being investigated as a potentially rapid-acting therapeutic for treatment-resistant depression (TRD) with at-home administration.atai to contextualize the upcoming Phase 2a topline results at its R&D D
- GlobeNewswire
atai Life Sciences Announces R&D Day Agenda
NEW YORK and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the agenda for its virtual R&D Day. During this event, management and scientific leaders will provide a comprehensive review of atai’s diversified mental health pipeline. The event will also provide updates on near-term catalysts, with a focus on the upcoming Phase 2a toplin
- GlobeNewswire
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
– atai has initiated a Phase 1 proof-of-concept clinical trial to demonstrate the safety, tolerability, and direct-to-brain delivery of intranasal INB-01, a sol-gel based drug-delivery technology. – INB-01 may enable direct-to-brain delivery of various compounds in development across atai’s pipeline, with topline results expected in H1 2023. – Potential advantages may include ease of administration, increased patient compliance, lower dose requirements, rapid onset of action, and minimized syste
GlobeNewswireIntelGenx’s Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate
SAINT LAURENT, Quebec, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today provided an update on its collaboration with its strategic partner, atai Life Sciences (NASDAQ:ATAI) (“atai”), for the development of novel formulations of pharmaceutical-grade psychedelics based on IntelGenx's polymeric film technologies. Pursuant to the first of two current feasibility agreements between the companies, IntelGenx conducted pre-development, formula
- GlobeNewswire
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
– Initial results showed that single ascending oral dosing of KUR-101 produces dose-dependent analgesia (pain relief) with effects on respiration comparable to that of placebo. – Topline results, including Part 2 comparing a single dose of KUR-101 to a single dose of oxycodone or placebo, are expected by the end of 2022. – KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD). – Ne